Clinical Trial Update: A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update discussing nausea and vomiting in breast cancer patients treated with trastuzumab deruxtecan (T-DXd); the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Breast Cancer Patients Treated With T-DXd | Phase 4 | Status: NOT_YET_RECRUITING